Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
324 Results Found
Chair File: The Importance of Legal Advocacy
Advocacy is such an important part of what we do as hospitals and health systems — and what the AHA does on behalf of our field — to help ensure that we get the resources we need to care for our communities.
AHA report: Hospitals are complying with 340B rules, but drug companies are not
The AHA June 16 released a report showing hospitals that participated in the 340B Drug Pricing Program are not only subject to disproportionately greater oversight by the federal government, but they also significantly outperform drug companies in terms of program compliance.
More Drug Company Oversight Needed to Maintain Compliance with 340B Program Rules
Not only are 340B Drug Pricing Program hospitals subject to disproportionately greater oversight by the federal government, they outperform drug companies in terms of program compliance to a substantial degree. These discrepancies underscore the need for increased federal oversight of drug manufacturers, as well as rejection of their unlawful approach to convert the discount program to a rebate model.
340B Advocacy Alliance Bulletin - June 13, 2025
AHA Post-Acute Care Advocacy Alliance News Update - June 13, 2025
Advocacy Issue: 340B Drug Pricing Program
The 340B program has worked successfully for over 30 years to allow eligible providers to stretch limited federal resources to provide more comprehensive programs and services to more patients. This is exactly what Congress intended when it created the program in 1992.
Hospitals That Have Committed to the 340B Principles
To ensure good stewardship of the 340B program, hospitals participating in the program should structure hospital policies and practices to demonstrate their commitment. That demonstration of commitment includes sharing publicly how 340B savings are used to benefit the community, by, for example reaching more eligible patients and providing more comprehensive services for those in the community. The following hospitals have taken that commitment.
The 340B Drug Pricing Program
For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs. Despite significant oversight from HRSA and the program’s proven record of decreasing government spending and expanding access to patient care, some want to scale it back or drastically reduce the benefits that eligible hospitals and their patients receive from the program.
AHA files brief defending Tennessee’s 340B contract pharmacy law
The AHA June 4 filed an amicus brief (https://www.aha.org/amicus-brief/2025-06-04-aha-files-brief-defending-tennessees-340b-contract-pharmacy-law) in the U.S. District Court for the Middle District of Tennessee in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies.
AHA Files Brief Defending Tennessee’s 340B Contract Pharmacy Law
AHA files brief defending Tennessee’s 340B contract pharmacy law.